FDA Announces Public Advisory Committee Meeting for Andexxa Supplemental Biologics License Application

Summary

The FDA is hosting a public meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee to provide advice on a supplemental biologics license application for Andexxa, a treatment for bleeding disorders, submitted by AstraZeneca AB.